Annelise vuidepot
Senior Vice President Chief Technology Officer - Head of Pipeline and Platform Research and UK Site Head Immunocore
Annelise joined Immunocore when it was founded (as Avidex) in 2000 and has played a lead role in the design and engineering of the ImmTAX platform, pioneering a novel class of TCR based therapeutics.
She is currently leading Immunocore’s drug discovery pipeline and research to expand the ImmTAX technology further. She is also Immunocore’s UK Site Head.
Before joining Immunocore, Annelise was a postdoctoral researcher in the Biochemistry department at University College London. She gained her master’s degree in chemistry from the University of Paris and her PhD in Biophysics from the École Polytechnique in Saclay, France.
Seminars
Monday 8th June 2026
Exploring a Novel Mechanism of Action with the Development of TCR– PD-1 Agonist Bispecifics for the Treatment of Autoimmune Diseases
4:00 pm
- Aiming to deliver tissue-specific TCR-based therapeutics
- Adapting the ImmTAC platform with a novel effector function to address autoimmune diseases
- Exploring the development of a beta-cell–targeted immune-suppressive PD-1 agonist bispecific to treat type I diabetes
